Hormone Or Derivative Affecting Or Utilizing Patents (Class 514/9.7)
  • Patent number: 10369237
    Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 6, 2019
    Assignee: 3-D Matrix, LTD.
    Inventors: Eun Seok Gil, Karl Patrick Gilbert
  • Patent number: 10323062
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 18, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10308698
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 4, 2019
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • Patent number: 10093707
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: October 9, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Patent number: 10093916
    Abstract: A method for the reduction or inactivation of viral and microbial content in the manufacturing of pancreatin API is disclosed. The method includes treating animal-derived tissue with peracetic acid to reduce viral activity and bacterial load prior to processing. In particular, the method includes treating porcine pancreas glands with peracteic acid prior to extracting a pancreatin API from the treated glandular tissue.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: October 9, 2018
    Assignee: Scientific Protein Laboratories, LLC
    Inventors: Kenneth S. Manning, Yan Wang, Dustin Nielsen, Ryan Ruf, Colin Crowley, Jon Restivo, Dana Spangenberg, Karla Anhalt, Mark Romich, Anisha Akula, Carmen Fritz
  • Patent number: 9993534
    Abstract: A vaccine comprising Calnexin fragment and a method of using the vaccine to immunize a patient against fungi are disclosed. The Calnexin fragment may be either a full-length native version or a functionally equivalent version of full-length Calnexin.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 12, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Bruce Steven Klein, Theodore Tristan Brandhorst, Thomas Sullivan, Marcel Wuethrich
  • Patent number: 9974825
    Abstract: The present invention is related to the peptide Des-[Asp1]-[Ala1]-Angiotensin-(1-7) (Ala1-Arg2-Val3-Tyr4-Ile5-His6-Pro7) (SEQ ID NO: 1) and/or its related compounds as vasodilating and cardioprotective agents to be used in mammals. This invention also comprises the production of compounds containing Des-[Asp1]-[Ala1]-Angiotensin-(1-7) and/or its related compounds and its use in methods for treating and preventing diseases.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: May 22, 2018
    Assignee: UNIVERSIDADE FEDERAL DE MINAS GERAIS
    Inventors: Robson Augusto Souza dos Santos, Anderson José Ferreira, Rubén Dario Sinisterra, Rodrigo Araújo Fraga da Silva, Roberto Queiroga Lautner
  • Patent number: 9925178
    Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: March 27, 2018
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • Patent number: 9708377
    Abstract: A novel peptide analogue of the Heterometrus spinnifer toxin HsTX1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (MS) or rheumatoid arthritis (RA). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (WT) peptide sequence (or a position corresponding to position 14 of the WT peptide sequence). The analogue exhibits selectivity for Kv1.3 over Kv1.1 and other potassium channels relative to the WT peptide.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: July 18, 2017
    Assignees: Monash University, Baylor College of Medicine, Peptides International, Inc.
    Inventors: Raymond S. Norton, Serdar Kuyucak, M Harunur Rashid, Michael Pennington, Christine Beeton
  • Patent number: 9701650
    Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 11, 2017
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
  • Patent number: 9393288
    Abstract: The invention relates to methods for modulating PPAR-? activity using relaxin or agonists thereof. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including small vessel disorders of the brain and those associated with increased blood-brain barrier permeability, cognitive disorders such as Alzheimer's disease, vascular dementia, epilepsy, stroke, CADASIL and migraine.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 19, 2016
    Assignee: The University of Vermont and State Agricultural College
    Inventor: Marilyn J. Cipolla
  • Patent number: 9220926
    Abstract: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: December 29, 2015
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Cotsarelis, Mayumi Ito
  • Patent number: 9198903
    Abstract: There is provided the use of a 5-HT2A receptor antagonist to treat or prevent thrombosis, particularly arterial thrombosis, in a human or animal patient. The patient is suitably one who is at risk of bleeding, particularly those about to undergo, or those undergoing, surgery. A preferred 5-HT2A antagonist is thromboserin.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: December 1, 2015
    Assignee: Thromboserin Limited
    Inventor: Mark Ian Munro Noble
  • Patent number: 9187525
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: November 17, 2015
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Patent number: 9066916
    Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 30, 2015
    Assignee: CORTHERA, INC.
    Inventors: Elaine Unemori, Sam Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
  • Patent number: 9050314
    Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to arthritis and/or arthritis-related conditions, including: gout, rheumatoid arthritis (RA), osteoarthritis (OA), and pseudogout, and/or inflammation resulting from any of the conditions Additional aspects provide methods for combination or adjunctive therapies (with anti-inflammatories, etc.). Methods to modulate immune response are also encompassed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: June 9, 2015
    Assignee: CMI Research Management, LLC
    Inventor: Richard N. Ushijima
  • Publication number: 20150147283
    Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 28, 2015
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Publication number: 20150147390
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventor: Mir Imran
  • Publication number: 20150141337
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Publication number: 20150141336
    Abstract: The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Rasmus Joergensen, Soeren Oestergaard, Lars Ynddal, Flemming Seier Nielsen
  • Publication number: 20150139944
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Patent number: 9034359
    Abstract: The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 19, 2015
    Assignee: Lidds AB
    Inventors: Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
  • Patent number: 9035021
    Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: May 19, 2015
    Assignee: Novartis AG
    Inventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
  • Patent number: 9029331
    Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
  • Publication number: 20150118185
    Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventor: Paul L. DeAngelis
  • Publication number: 20150119320
    Abstract: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: UDI EYAL FIMA, OREN HERSHKOVITZ
  • Publication number: 20150111823
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin Dong, John E Taylor, Rakesh Datta, Michael DeWitt Culler
  • Publication number: 20150111824
    Abstract: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 23, 2015
    Inventors: Robert N. JENNINGS, John T.H. ONG, Christopher A. RHODES, Gregg STETSKO, Steven J. PRESTRELSKI
  • Patent number: 9011933
    Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.
    Type: Grant
    Filed: January 23, 2005
    Date of Patent: April 21, 2015
    Assignee: Biomas Ltd.
    Inventors: Benjamin Sredni, Michael Albeck
  • Patent number: 9011309
    Abstract: An electromagnetic radiation activated device comprises a property changing material and at least one functionalized fullerene that upon irradiation of the functionalized fullerenes with electromagnetic radiation of one or more frequencies a thermally activated chemical or physical transformation occurs in the property changing material. The thermal activated transformation of the property changing material is triggered by the heating or combustion of the functionalized fullerenes upon their irradiation. The device can include a chemical agent that is embedded in the property changing material and is released when the material is heated by the functionalized fullerenes upon irradiation.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 21, 2015
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Vijay Krishna, Karl Zawoy, Brij M. Moudgil, Benjamin L. Koopman, Nathanael Ian Stevens, Kevin William Powers
  • Publication number: 20150099702
    Abstract: This invention is directed to the compositions and methods for inducing female gonad maturation in crustacean species such as shrimp, lobster or crab. In one embodiment, the composition for inducing gonad maturation comprises a dsRNA corresponding to the GIH DNA, recombinant protein of a gonad stimulatory hormone (GSH) and farnesoic acid (FA). In another embodiment, the composition for inducing gonad maturation comprises a dsRNA corresponding to the GIH DNA, recombinant MeMIH-B protein and farnesoic acid (FA).
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventor: Siu Ming CHAN
  • Patent number: 8999935
    Abstract: The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: April 7, 2015
    Assignee: New York University
    Inventor: Xi Huang
  • Patent number: 8999930
    Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 7, 2015
    Assignee: PharmaIN Corporation
    Inventors: Gerardo M. Castillo, Elijah M. Bolotin
  • Patent number: 8999670
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: April 7, 2015
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Publication number: 20150094264
    Abstract: The present invention relates to the use of obestatin, or to the nucleotide sequence that codes for same, as an in vitro myogenic agent, and for the production of a drug for muscle regeneration, preferably for musculoskeletal regeneration, thus being useful in the treatment and/or prevention of degenerative or genetic diseases or of lesions that present with muscle damage.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 2, 2015
    Applicants: SERVIZO GALEGO DE SAUDE
    Inventors: Jesús Pérez Camiña, Felipe Casanueva Freijo
  • Patent number: 8993521
    Abstract: The present invention relates to a liquid oral pharmaceutical composition of desmopressin, and its use for the treatment of central diabetes insipidus, primary nocturnal enuresis, bleeding in patients with Hemophilia A, with von Willebrand-Jürgens disease and postoperative bleeding.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: March 31, 2015
    Assignees: GP Pharm, S.A., Laboratorio Reig Jofre, S.A.
    Inventors: Nuria Carbajal Navarro, Antonio Boix Montanes, Carlos Nieto Abad, Antonio Parente Duena, Ricard Mis Vizcaino, Cesar Garcia Plumed
  • Publication number: 20150086607
    Abstract: A synthetic construct suitable for implantation into a biological organism that includes at least one polymer scaffold; wherein the at least one polymer scaffold includes at least one layer of polymer fibers that have been deposited by electrospinning; wherein the orientation of the fibers in the at least one polymer scaffold relative to one another is generally parallel, random, or both; and wherein the at least one polymer scaffold has been adapted to function as at least one of a substantially two-dimensional implantable structure and a substantially three-dimensional implantable tubular structure.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Jed K. JOHNSON, Ross KAYUHA
  • Publication number: 20150087718
    Abstract: Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1 A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein, and packaging containing printed material describing use and indications for the product.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: Janette M McAllister, Jerome F Strauss
  • Publication number: 20150086605
    Abstract: The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.
    Type: Application
    Filed: February 5, 2013
    Publication date: March 26, 2015
    Inventors: Joshua R. Mauney, Carlos R. Estrada, David L. Kaplan, Eun Seok Gil
  • Patent number: 8980300
    Abstract: A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: March 17, 2015
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Stephen Dirk Pacetti, Yiwen Tang, Syed Faiyaz Ahmed Hossainy
  • Patent number: 8980295
    Abstract: Biomaterials that support cell attachment and growth are provided. In one aspect, biomaterials are provided comprising a first polymer matrix comprising reactive amino moieties and a second polymer matrix that interpenetrates with the first polymer matrix, where the second polymer matrix comprises a poly(alkylene oxide) comprising two or more alkylene oxide oligomers joined by gamma-thioether carbonyl linkages. In another aspect, biomaterials are provided comprising at least one biopolymer comprising amino groups, thiol groups, and bifunctional modifiers connecting at least some of the amino groups to at least some of the thiol groups; and at least one poly(alkylene oxide) cross-linked to at least two thiol groups of the biopolymer. The biomaterials may further comprise a pharmacologically active agent or cells. Methods of administering such biomaterials to a patient in need thereof are also provided.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: March 17, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Weiyuan J. Kao, Yao Fu
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150072932
    Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 12, 2015
    Inventors: Geraldine Siegfried, Abdel-Majid Khatib
  • Publication number: 20150072924
    Abstract: This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/Glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/Glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of said agonist.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Oren Hershkovitz
  • Publication number: 20150072930
    Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 12, 2015
    Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150057216
    Abstract: The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on Angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided.
    Type: Application
    Filed: December 14, 2012
    Publication date: February 26, 2015
    Inventors: Paul Beringer, Richard Franklin
  • Publication number: 20150057219
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
  • Publication number: 20150051150
    Abstract: Provided herein are methods of reducing and/or inhibiting A deposition or A plaque formation in the brain, and/or inhibiting or slowing the progression of disorders mediated by A deposition or A plaque formation using therapeutically effective amounts of amylin agonist compounds or pharmaceutical compositions comprising amylin agonist compounds. As demonstrated herein, amylin and amylin analog administration improves cognition, including memory. Also provided herein are non-invasive, inexpensive amylin or amylin analog challenge assays and methods and kits thereof for detecting the presence of plaques comprising A? peptide in the brain, and for identifying individuals at increased risk for Alzheimer's disease (AD) and/or amnestic mild cognitive impairment.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: Wendy Wei Qiao Qui
  • Publication number: 20150045295
    Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 12, 2015
    Inventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville